- Aequus (AQS) has received Health Canada’s approval for Zimed PF (Bimatoprost 0.03 per cent)
- Zimed PF is intended to reduce elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension
- The company plans to launch the product in 2023
- Aequus is a specialty pharmaceutical company focused on developing and commercializing high-quality, differentiated products
- Aequus Pharmaceuticals (AQS) closed up by 60 per cent, trading at $0.04 per share
Aequus (AQS) has received Health Canada’s approval for Zimed PF (Bimatoprost 0.03 per cent).
Zimed PF is intended to reduce elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
The medication is a prostaglandin analog (PGA) that leverages a unidirectional valve and air filter technology to eliminate the need for a preservative, meaning it is less likely to cause Ocular Surface Disease in patients.
Glaucoma is one of the leading causes of blindness in North America, affecting more than 700,000 Canadians.
“We have heard from the eyecare professionals that there is a need for preservative-free alternatives,” stated Grant Larsen, Aequus’ CCO. “The PGA market continues to grow year-over-year, and we are excited to provide a new option for Canadian healthcare providers and their patients.”
“We want to thank Medicom for their support through the approval process with Health Canada,” added Doug Janzen, Aequus’ CEO. “This is the third product we’ve brought to Canada in this partnership. We look forward to launching Zimed in 2023 and providing Canadians with more treatment options.”
Aequus is a specialty pharmaceutical company focused on developing and commercializing high-quality, differentiated products. Its portfolio includes commercial products in ophthalmology and optometry.
Aequus Pharmaceuticals (AQS) closed up by 60 per cent, trading at $0.04 per share.